Patients with renal cell carcinoma experienced prolonged disease stabilization under co-administration of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in a phase I study [44]. Here, HDAC9 is linked to hereditary clear cell renal cell carcinoma.